Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450629 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Efficacy of PDP-716
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
- 20
- Study locations
NCT03450629 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 682 participants, above the 266-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03450629, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
Conditions Studied
Interventions
- DRUG Brimonidine Tartrate Ophthalmic Suspension
- DRUG Brimonidine Tartrate Ophthalmic Solution
Study Locations (20)
Florida
- SPARC Site 11 - Coral Springs
- SPARC Site 29 - Deerfield Beach
- SPARC Site 34 - Fort Myers
- SPARC Site 46 - Hollywood
- SPARC Site 21 - Jacksonville
- SPARC Site 35 - Miami
- SPARC Site 27 - Miami
- SPARC Site 10 - Miami
- SPARC Site 16 - Miami
California
- SPARC Site 38 - Burbank
- SPARC Site 44 - Glendale
- SPARC Site 45 - Glendale
- SPARC Site 43 - Mission Hills
- SPARC Site 1 - Newport Beach
- SPARC Site 14 - Santa Barbara
- SPARC Site 47 - Torrance
Arizona
- SPARC Site 4 - Chandler
- SPARC Site 5 - Prescott
- SPARC Site 3 - Sun City
Colorado
- SPARC Site 7 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03450629
The ClinicalTrials.gov registry entry for NCT03450629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 266-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (156% higher). The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Brimonidine Tartrate Ophthalmic Suspension is the first listed.
NCT03450629 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03450629 about?
NCT03450629 is a clinical study titled "Evaluation of Safety and Efficacy of PDP-716". The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
What is the current status of trial NCT03450629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2018-09-13. Estimated completion is 2020-12-01.
What conditions does trial NCT03450629 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT03450629?
The interventions under investigation include: Brimonidine Tartrate Ophthalmic Suspension (DRUG), Brimonidine Tartrate Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03450629?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03450629 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.